Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

510.38
-5.0800-0.99%
Post-market: 510.380.00000.00%19:30 EDT
Volume:538.52K
Turnover:275.07M
Market Cap:21.89B
PE:18.26
High:515.55
Open:510.95
Low:507.03
Close:515.46
52wk High:609.35
52wk Low:375.61
Shares:42.89M
Float Shares:39.35M
Volume Ratio:1.27
T/O Rate:1.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.42
PE(LYR):18.32

Loading ...

United Therapeutics CEO Chairperson Martine Rothblatt disposes of common shares worth $5.2 million

Reuters
·
Jun 10

United Therapeutics CEO Martine Rothblatt disposes of common shares worth $5.19 million

Reuters
·
Jun 09

United Therapeutics CFO James Edgemond disposes of 8,000 shares worth $4.36 million

Reuters
·
Jun 06

United Therapeutics Chairperson and CEO Martine Rothblatt reports UTHR share disposal worth $4.25 million

Reuters
·
Jun 06

Will Positive TETON-1 IPF Data and Space R&D Shift United Therapeutics' (UTHR) Innovation Narrative?

Simply Wall St.
·
Jun 06

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)

TIPRANKS
·
Jun 06

United Therapeutics EVP, General Counsel Paul A. Mahon disposes of common shares worth $4.68 million

Reuters
·
Jun 05

United Therapeutics CEO Martine Rothblatt disposes of shares worth $5.1 million

Reuters
·
Jun 04

United Therapeutics CFO James Edgemond disposes of common shares worth $4.87 million

Reuters
·
Jun 03

United Therapeutics Chairperson and CEO Martine Rothblatt disposes of USD 4.75 million in common shares

Reuters
·
Jun 02

United Therapeutics CFO James Edgemond disposes of 10,000 common shares worth $5.66 million

Reuters
·
May 30

United Therapeutics Chairperson, CEO Martine Rothblatt disposes of USD 4.63 million in common shares

Reuters
·
May 30

United Therapeutics CEO Chairperson Martine Rothblatt disposes of USD 5.02 million in common shares

Reuters
·
May 29

PHINDER Trial Update: How Earlier Pulmonary Hypertension Screening Could Shape United Therapeutics’ Market

TIPRANKS
·
May 29

United Therapeutics CFO James Edgemond sells USD 4.17 million in common shares

Reuters
·
May 28

United Therapeutics Advances High-Risk, High-Reward Xenokidney Trial for ESRD

TIPRANKS
·
May 28

United Therapeutics CFO James Edgemond presents at Jefferies Global Healthcare Conference

Reuters
·
May 27

United Therapeutics CEO Martine Rothblatt sells common shares worth $5.37 million

Reuters
·
May 27

Assessing United Therapeutics (UTHR) Valuation After Strong Recent Shareholder Returns

Simply Wall St.
·
May 26

United Therapeutics CFO James Edgemond disposes of shares worth $5.64 million

Reuters
·
May 23